Phase IIb trial of an oral formulation of testosterone undecanoate in adult males with primary or secondary hypogonadism.

Trial Profile

Phase IIb trial of an oral formulation of testosterone undecanoate in adult males with primary or secondary hypogonadism.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2015

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism
  • Focus Therapeutic Use
  • Sponsors SOV Therapeutics
  • Most Recent Events

    • 08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.
    • 24 Dec 2014 New trial record
    • 16 Dec 2014 Primary endpoint has been met (testosterone replacement), according to a SOV Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top